JP2022502492A5 - - Google Patents
Info
- Publication number
- JP2022502492A5 JP2022502492A5 JP2021540380A JP2021540380A JP2022502492A5 JP 2022502492 A5 JP2022502492 A5 JP 2022502492A5 JP 2021540380 A JP2021540380 A JP 2021540380A JP 2021540380 A JP2021540380 A JP 2021540380A JP 2022502492 A5 JP2022502492 A5 JP 2022502492A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- thiamine
- composition according
- patient
- administered
- Prior art date
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024125670A JP2024161416A (ja) | 2018-09-25 | 2024-08-01 | 骨髄増殖性疾患の治療法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862736369P | 2018-09-25 | 2018-09-25 | |
| US62/736,369 | 2018-09-25 | ||
| US201862783076P | 2018-12-20 | 2018-12-20 | |
| US62/783,076 | 2018-12-20 | ||
| PCT/US2019/052608 WO2020068755A1 (en) | 2018-09-25 | 2019-09-24 | Methods of treating myeloproliferative disorders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024125670A Division JP2024161416A (ja) | 2018-09-25 | 2024-08-01 | 骨髄増殖性疾患の治療法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022502492A JP2022502492A (ja) | 2022-01-11 |
| JP2022502492A5 true JP2022502492A5 (https=) | 2022-10-03 |
| JPWO2020068755A5 JPWO2020068755A5 (https=) | 2022-10-03 |
Family
ID=69950867
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021540380A Pending JP2022502492A (ja) | 2018-09-25 | 2019-09-24 | 骨髄増殖性疾患の治療法 |
| JP2024125670A Pending JP2024161416A (ja) | 2018-09-25 | 2024-08-01 | 骨髄増殖性疾患の治療法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024125670A Pending JP2024161416A (ja) | 2018-09-25 | 2024-08-01 | 骨髄増殖性疾患の治療法 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20220031699A1 (https=) |
| EP (1) | EP3856169A4 (https=) |
| JP (2) | JP2022502492A (https=) |
| KR (2) | KR20210102192A (https=) |
| CN (1) | CN113286584A (https=) |
| AU (1) | AU2019346521B2 (https=) |
| BR (1) | BR112021005518A2 (https=) |
| CL (1) | CL2021000744A1 (https=) |
| IL (1) | IL281736A (https=) |
| MA (1) | MA53741A (https=) |
| MX (2) | MX2021003450A (https=) |
| MY (1) | MY209349A (https=) |
| SG (1) | SG11202103019WA (https=) |
| WO (1) | WO2020068755A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3856189A4 (en) * | 2018-09-25 | 2022-06-29 | Impact Biomedicines, Inc. | Methods of treating myeloproliferative disorders |
| WO2020068755A1 (en) | 2018-09-25 | 2020-04-02 | Impact Biomedicines, Inc. | Methods of treating myeloproliferative disorders |
| EP3923948A4 (en) | 2019-02-12 | 2022-11-16 | Impact Biomedicines, Inc. | CRYSTALLINE SHAPES OF A JAK2 INHIBITOR |
| JP2024501640A (ja) * | 2020-12-16 | 2024-01-15 | インパクト バイオメディシンズ インコーポレイテッド | フェドラチニブの投薬 |
| MX2023009858A (es) | 2021-02-25 | 2023-09-12 | Impact Biomedicines Inc | Uso de inhibidores de proteina de bromodominio y motivo extraterminal (bet) solo o en combinacion con fedratinib o ruxolitinib como tratamiento para una malignidad hematologica tal como la mielofibrosis. |
| WO2023044297A1 (en) | 2021-09-14 | 2023-03-23 | Impact Biomedicines, Inc. | Fedratinib for treating myeloproliferative disorders |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103626742B (zh) * | 2005-11-01 | 2017-04-26 | 塔格根公司 | 激酶的联-芳基间-嘧啶抑制剂 |
| US8133900B2 (en) | 2005-11-01 | 2012-03-13 | Targegen, Inc. | Use of bi-aryl meta-pyrimidine inhibitors of kinases |
| US20090093009A1 (en) * | 2007-10-09 | 2009-04-09 | Sum Chan | Mass spectrometry method for measuring thiamine in body fluid |
| CA2816957A1 (en) | 2010-11-07 | 2012-05-10 | Targegen, Inc. | Compositions and methods for treating myelofibrosis |
| US20130102624A1 (en) * | 2011-05-19 | 2013-04-25 | John V. Schloss | Early detection of thiamine deficiency |
| US10155987B2 (en) | 2012-06-12 | 2018-12-18 | Dana-Farber Cancer Institute, Inc. | Methods of predicting resistance to JAK inhibitor therapy |
| WO2015081127A2 (en) | 2013-11-26 | 2015-06-04 | Gilead Sciences, Inc. | Therapies for treating myeloproliferative disorders |
| CA2936865A1 (en) * | 2014-01-31 | 2015-08-06 | Dana-Farber Cancer Institute, Inc. | Diaminopyrimidine benzenesulfone derivatives and uses thereof |
| HK1256638A1 (zh) * | 2015-08-04 | 2019-09-27 | Acceleron Pharma Inc. | 用於治疗骨髓增生性病症的方法 |
| WO2020068755A1 (en) | 2018-09-25 | 2020-04-02 | Impact Biomedicines, Inc. | Methods of treating myeloproliferative disorders |
| EP3856189A4 (en) | 2018-09-25 | 2022-06-29 | Impact Biomedicines, Inc. | Methods of treating myeloproliferative disorders |
| FR3092581A1 (fr) | 2019-02-12 | 2020-08-14 | Impact Biomedicines, Inc | Formes cristallines d'un inhibiteur de jak2 |
| EP3923948A4 (en) | 2019-02-12 | 2022-11-16 | Impact Biomedicines, Inc. | CRYSTALLINE SHAPES OF A JAK2 INHIBITOR |
-
2019
- 2019-09-24 WO PCT/US2019/052608 patent/WO2020068755A1/en not_active Ceased
- 2019-09-24 AU AU2019346521A patent/AU2019346521B2/en active Active
- 2019-09-24 MY MYPI2021001641A patent/MY209349A/en unknown
- 2019-09-24 EP EP19866319.7A patent/EP3856169A4/en active Pending
- 2019-09-24 BR BR112021005518-5A patent/BR112021005518A2/pt unknown
- 2019-09-24 MA MA053741A patent/MA53741A/fr unknown
- 2019-09-24 JP JP2021540380A patent/JP2022502492A/ja active Pending
- 2019-09-24 US US17/279,765 patent/US20220031699A1/en not_active Abandoned
- 2019-09-24 KR KR1020217012234A patent/KR20210102192A/ko not_active Ceased
- 2019-09-24 CN CN201980070403.4A patent/CN113286584A/zh active Pending
- 2019-09-24 MX MX2021003450A patent/MX2021003450A/es unknown
- 2019-09-24 KR KR1020257037570A patent/KR20250164332A/ko active Pending
- 2019-09-24 SG SG11202103019WA patent/SG11202103019WA/en unknown
-
2021
- 2021-03-22 IL IL281736A patent/IL281736A/en unknown
- 2021-03-24 MX MX2023013844A patent/MX2023013844A/es unknown
- 2021-03-25 CL CL2021000744A patent/CL2021000744A1/es unknown
- 2021-12-23 US US17/560,373 patent/US11400092B2/en active Active
-
2024
- 2024-08-01 JP JP2024125670A patent/JP2024161416A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022502492A5 (https=) | ||
| JP6984024B2 (ja) | Ｃｙｐ３ａ４基質薬物による処置方法 | |
| Crosby et al. | Amantadine in Parkinson's disease | |
| JP2609968B2 (ja) | グリシン／ｎｍｄａ受容体複合体の機能性拮抗剤による情緒障害の治療 | |
| TWI353835B (en) | Novel methods for identifying improved, non-sedati | |
| CN101563086B (zh) | 睾酮和5-ht1a激动剂在治疗性功能障碍中的应用 | |
| KR20250136946A (ko) | 트라디피턴트에 의한 치료 방법 | |
| JP2021526138A5 (https=) | ||
| EP3010505A1 (en) | Pharmaceutical combinations | |
| JP2024019691A (ja) | 肺動脈性高血圧症および他疾患に関連する肺動脈性肺高血圧症の治療法 | |
| US20060173074A1 (en) | Treatment of restless legs syndrome | |
| JP2021046394A5 (https=) | ||
| US20250170109A1 (en) | Method of treating malignant tumor by azabicyclic compound | |
| AU2018234903B2 (en) | Combination therapies for the treatment of breast cancer | |
| CN104039148A (zh) | 组合als疗法 | |
| RU2015119377A (ru) | Лекарственные формы леводопы для быстрого купирования болезни паркинсона | |
| CN101610760A (zh) | 恶病质的治疗 | |
| US20120071464A1 (en) | Method of treatment of obsessive compulsive disorder with ondansetron | |
| JPWO2020068755A5 (https=) | ||
| PL211211B1 (pl) | Zestawienie propionylo-L-karnityny z sildenafilem, kompozycja farmaceutyczna je zawierająca i jego zastosowanie | |
| JP2006508118A5 (https=) | ||
| US20170266132A1 (en) | Method for treating hyperhidrosis | |
| WO2019004465A1 (ja) | ペマフィブラートを含有する医薬 | |
| JPWO2019226685A5 (https=) | ||
| JP6420923B1 (ja) | 医薬 |